Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care

Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care - an economic evaluation. Critical Care 2015, 19: 67

Turunen, H., et al.

http://ccforum.com/content/19/1/67/abstract

Dexmedetomidine was shown in two European randomized double-blind double-dummy trials (PRODEX and MIDEX) to be non-inferior to propofol and midazolam in maintaining target sedation levels in mechanically ventilated intensive care unit (ICU) patients. Additionally, dexmedetomidine shortened the time to extubation versus both standard sedatives, suggesting it may reduce ICU resource needs and thus lower ICU costs.